Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int

More documents

Recommendations

Info

148 202. Mitchell SK, Kelly KJ, Potgieter FE, Moon MW. Assessing social preparedness for antiretroviral therapy in a generalized AIDS epidemic: a diffusion of innovations approach. AIDS Behav 2009;13(1):76-84. 203. Orrell C. Antiretroviral adherence in a resource-poor setting. Curr HIV/AIDS Rep 2005;2(4):171-6. 204. Sodergard B, Hofer S, Halvarsson M, Sonnerborg A, Tully MP, Lindblad AK. A structural equation modeling approach to the concepts of adherence and readiness in antiretroviral treatment. Patient Educ Couns 2007;67(1-2):108-16. 205. Tabarsi P, Saber-Tehrani AS, Baghaei P, Padyab M, Mansouri D, Amiri M, et al. Early initiation of antiretroviral therapy results in decreased morbidity and mortality among patients with TB and HIV. J Int AIDS Soc 2009;12(1):14. 206. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS ONE 2009;4(5):e5575. 207. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010;5(1):18-26. 208. WHO. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. 2009 Progress Report. 2009. 209. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1discordant couples in Rakai, Uganda. Lancet 2001;357(9263):1149-53. 210. Pao D, Pillay D, Fisher M. Potential impact of early antiretroviral therapy on transmission. Curr Opin HIV AIDS 2009;4(3):215-21. 211. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010;375(9709):123- 31. 212. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV- 1-infected patients in the first year of antiretroviral therapy: comparison between lowincome and high-income countries. Lancet 2006;367(9513):817-24. 213. Effectiveness of HIV viral load monitoring of patient outcome in resource-poor settings [database on the Internet]2009 [cited Februrary 28, 2010]. Available from: http:// clinicaltrials.gov/ct2/show/NCT00929604?term=Saag&cntry1=AF:ZM&rank=1. 214. Monitoring highly active antiretroviral therapy in HIV-infected parentsin Thailand [database on the Internet] 2009 Last Updated: September 14 [cited February 18, 2010]. Available from: http://clinicaltrials.gov/ct2/show/NCT00162682?term=Lallemant&cntry1=SE:TH&ra nk=4. TraTamienTo anTirreTroviral de la infección por el viH en adulTos y adolescenTes recomendaciones para un enfoque de salud pública
215. Antiretroviral treatment simplified follow-up management assessment (ANRS 12110 STRATALL) [database on the Internet] 2008 Last updated: April 16, 2008. Available from: http://clinicaltrials.gov/ct2/show/NCT00301561?term=Laurent&cntry1=AF:CM&rank=1. 216. Goicoechea M, Liu S, Best B, Sun S, Jain S, Kemper C, et al. Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reversetranscriptase inhibitor-based therapy. J Infect Dis 2008;197(1):102-8. 217. Mohsen AH, Easterbrook PJ, Taylor C, Portmann B, Kulasegaram R, Murad S, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003;52(7):1035-40. 218. Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitisrelated mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008;47(2):221-5. 219. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999;30(4):1054-8. 220. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009;49(10):1605-15. 221. Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, et al. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection? Antivir Ther 2005;10(7):779-90. 222. Roche. Copegus (ribavirin, USP) prescibing information. 2010. 223. Bani-Sadr F, Denoeud L, Morand P, Lunel-Fabiani F, Pol S, Cacoub P, et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr 2007;45(1):123-5. 224. Rodriguez-Torres M, Torriani FJ, Soriano V, Borucki MJ, Lissen E, Sulkowski M, et al. Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study. Antimicrob Agents Chemother 2005;49(10):3997-4008. 225. Mira JA, Lopez-Cortes LF, Barreiro P, Tural C, Torres-Tortosa M, de Los Santos Gil I, et al. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother 2008;62(6):1365-73. 149
Page 1 and 2:
Programa de VIH/SIDA Fortalecer los
Page 3:
TRATAMIENTO ANTIRRETROVIRAL DE LA I
Page 6 and 7:
iv 15. Poblaciones específicas - c
Page 9 and 10:
1. SIgLAS Y AbREVIATURAS 3TC lamivu
Page 11:
RTN recuento total de neutrófilos
Page 14 and 15:
6 Julian Gold (Universidad de New S
Page 16 and 17:
8 4. ANTECEDENTES La guía de la OM
Page 18 and 19:
10 6. PRINCIPIOS RECTORES Los princ
Page 20 and 21:
12 8. METODOLOgÍA Y PROCEDIMIENTO
Page 22 and 23:
14 del Rapid advice en Noviembre de
Page 24 and 25:
16 Fuerza de la recomendación Fund
Page 26 and 27:
18 10. ADAPTACIÓN DE LA gUÍA Las
Page 28 and 29:
20 11. RESUMEN DE CAMbIOS ANTES DE
Page 30 and 31:
22 Cuadro 5: Cuando iniciar tratami
Page 32 and 33:
24 Población Guía TARV 2010* Muje
Page 34 and 35:
26 clínicos del estadío clínico
Page 36 and 37:
28 Un inicio temprano significará
Page 38 and 39:
30 Septicemia recurrente (incluida
Page 40 and 41:
32 14. CON qUé INICIAR EL TARV 14.
Page 42 and 43:
34 Evidencia adicional surge de est
Page 44 and 45:
36 Población Mujeres embarazadas C
Page 46 and 47:
38 La revisión de la toxicidad del
Page 48 and 49:
40 14.9. TDF + 3TC (o FTC) + EFV Al
Page 50 and 51:
42 Sin embargo, algunas combinacion
Page 52 and 53:
44 Con qué iniciar Con respecto a
Page 54 and 55:
46 Exposición previa a ARVs para P
Page 56 and 57:
48 La biopsia hepática y los méto
Page 58 and 59:
50 más viable en entornos de recur
Page 60 and 61:
52 16. CUáNDO CAMbIAR EL TARV 16.1
Page 62 and 63:
54 16.4. Beneficios y riesgos Benef
Page 64 and 65:
56 Gráfico 1. Estrategia para frac
Page 66 and 67:
58 17. REgÍMENES DE SEgUNDA LÍNEA
Page 68 and 69:
60 CDF y son más costosos que las
Page 70 and 71:
62 Existen dos escenarios clínicos
Page 72 and 73:
64 18 REgÍMENES DE TERCERA LÍNEA
Page 74 and 75:
66 más alto que el EFV o la NVP. N
Page 76 and 77:
68 19. PAqUETE DE ATENCIÓN INTEgRA
Page 78 and 79:
70 19.6. Infecciones de transmisió
Page 80 and 81:
72 Etapa de la infección por HIV E
Page 82 and 83:
74 TDF EFV Alteraciones renales Enf
Page 84 and 85:
76 Nombre genérico Dosis Didanosin
Page 86 and 87:
78 21.3. Toxicidad y sustitución r
Page 88 and 89:
80 21.4. Efectos adversos relaciona
Page 90 and 91:
82 Evento clínico Diagnóstico cl
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
92 TraTamienTo anTirreTroviral de l
Page 102 and 103:
Page 104 and 105:
Page 106 and 107: 98 TraTamienTo anTirreTroviral de l
Page 108 and 109: 100 TraTamienTo anTirreTroviral de
Page 140 and 141: 132 15. Gange SJ, Kitahata MM, Saag
Page 142 and 143: 134 37. Arribas JR, Pozniak AL, Gal
Page 144 and 145: 136 59. Ananworanich J, Moor Z, Sia
Page 146 and 147: 138 83. Baylor MS, Johann-Liang R.
Page 148 and 149: 140 108. Arrive E, Kyabayinze DJ, M
Page 150 and 151: 142 131. Baleta A. Trial finds simu
Page 152 and 153: 144 155. Cozzi Lepri A, Phillips AN
Page 154 and 155: 146 177. M Hull Moore D, Harris M,
Page 158: 150 226. Montes Ramírez ML Rodríg
show all

Tratamiento antirretroviral de la infección por el VIH - libdoc.who.int

Create successful ePaper yourself

Delete template?

Save as template?